UCSF Files Appeal of United States Patent and Trademark Office Judgment in Favor of InSite Vision

Mon, 01/09/2012 - 5:35am
ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated today announced that the University of California, San Francisco (UCSF) has appealed the judgment of the United States Patent and Trademark Office (USPTO) panel that found in favor of the Company in its patent interference litigation with UCSF. The USPTO panel of judges entered judgment in favor of InSite Vision and confirmed the inventorship of InSite Visions U.S. Patent Nos. 6,239,113 and 6,569,443 protecting AzaSite® on November 25, 2011. The appeal was filed by UCSF with the U.S. Court of Appeals for the Federal Circuit in Washington, D.C. on December 23, 2011.

"We are disappointed that UCSF has chosen to appeal the judgment of the USPTO in this case," said Timothy Ruane, InSite Vision's Chief Executive Officer. "We strongly believe that the UCSF claims are entirely without merit as confirmed by the USPTO and we will continue to vigorously defend our position."

In 2009, the Regents of the University of California claimed that the inventions contained in the patents were made by a former employee of the University alone and without collaboration with InSite Vision, the assignee of all the named inventors.

About InSite Vision

InSite Vision is advancing new and superior ophthalmologic products for unmet eye care needs. The companys product portfolio utilizes InSite Visions proven DuraSite® bioadhesive polymer core technology, an innovative platform that extends the duration of drug retention on the surface of the eye, thereby reducing frequency of treatment and improving the efficacy of topically delivered drugs. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Merck, and Besivance® (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch + Lomb. InSite Visions clinical-stage ophthalmic product pipeline includes AzaSite Plus™ (ISV-502) and DexaSite™ (ISV-305) for the treatment of eye infections, BromSite™ (ISV-303) for pain and swelling associated with ocular surgery, and ISV-101 for the treatment of dry eye disease. For further information on InSite Vision, please visit

Posted by Sean Fenske, Editor-in-Chief, MDT



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.